Home Antibody All anti-SENP6 antibodies
Also for SENP6 (NM_001100409)
| Peptide with sequence C-KPKYEPNPHYHEN, from the internal region of the protein sequence according to NP_001093879.1; NP_056386.2.|
|Test: Human. Expected from seq similarity: Human, Mouse, Rat
||ELISA: 1:32,000. WB: 0.5-1.5µg/ml.
|Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.|
| Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. Aliquot and store at -20°C. Minimize freezing and thawing.
|Homo sapiens SUMO1/sentrin specific peptidase 6 (SENP6), transcript variant 2|
Entrez Gene 26054 Human
Entrez Gene 215351 Mouse
Entrez Gene 300860 Rat
|Ubiquitin-like molecules (UBLs), such as SUMO1 (UBL1; MIM 601912), are structurally related to ubiquitin (MIM 191339) and can be ligated to target proteins in a similar manner as ubiquitin. However, covalent attachment of UBLs does not result in degradation of the modified proteins. SUMO1 modification is implicated in the targeting of RANGAP1 (MIM 602362) to the nuclear pore complex, as well as in stabilization of I-kappa-B-alpha (NFKBIA; MIM 164008) from degradation by the 26S proteasome. Like ubiquitin, UBLs are synthesized as precursor proteins, with 1 or more amino acids following the C-terminal glycine-glycine residues of the mature UBL protein. Thus, the tail sequences of the UBL precursors need to be removed by UBL-specific proteases, such as SENP6, prior to their conjugation to target proteins (Kim et al., 2000 [PubMed 10799485]).[supplied by OMIM]. |
|ProteaseDruggable Genome |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
TA303331 (0.5µg/ml) staining of HeLa cell nuclear lysate (35µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.